Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.44 |
| ▸ | CNR2 | P34972 | 7/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422122 | 0.82 | NPC1 (0.53) | CNR1CNR2SLC6A9PPARAANO1 | |
| SCHEMBL10397371 | 0.76 | NPC1 (0.46) | CNR1CNR2GAANPC1RAB9A | |
| SCHEMBL14817465 | 0.75 | NOTUM (0.51) | SLC6A9GAA | |
| SCHEMBL5777771 | 0.74 | CNR1 (0.45) | CNR1CNR2GAANPC1RAB9A | |
| SCHEMBL421721 | 0.73 | CA12 (0.52) | SLC6A9RAB9A | |
| SCHEMBL24353844 | 0.72 | POLB (0.44) | CNR1CNR2NPC1RAB9A | |
| SCHEMBL9119278 | 0.72 | CNR1 (0.55) | CNR1CNR2NPC1RAB9A | |
| SCHEMBL10898642 | 0.72 | KMT2A (0.45) | CNR1CNR2NPC1RAB9A | |
| SCHEMBL423901 | 0.72 | GPR35 (0.41) | SLC6A9GAA | |
| SCHEMBL5361086 | 0.71 | CNR1 (0.44) | CNR1CNR2GAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585456-B1 | AMIDO-TROPANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-09-16 | — | — | EP | disclosed |
| EP-2470498-B1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-02-11 | — | — | EP | disclosed |
| EP-2470498-B1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-02-11 | — | — | EP | disclosed |
| EP-2531190-B1 | TETRAHYDRO-PYRAN DERIVATIVES AGAINST NEUROLOGICAL ILLNESSES | HOFFMANN LA ROCHE (CH) | 2014-07-23 | — | — | EP | disclosed |
| EP-2531190-B1 | TETRAHYDRO-PYRAN DERIVATIVES AGAINST NEUROLOGICAL ILLNESSES | HOFFMANN LA ROCHE (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-8524909-B2 | Tetrahydro-pyran derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524909-B2 | Tetrahydro-pyran derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524909-B2 | Tetrahydro-pyran derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2585456-A1 | AMIDO-TROPANE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-01 | — | — | EP | disclosed |
| US-8404673-B2 | Carbocyclic GlyT1 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| WO-2011095434-A1 | TETRAHYDRO-PYRAN DERIVATIVES AGAINST NEUROLOGICAL ILLNESSES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011095434-A1 | TETRAHYDRO-PYRAN DERIVATIVES AGAINST NEUROLOGICAL ILLNESSES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| US-20110190349-A1 | TETRAHYDRO-PYRAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-04 | — | — | US | disclosed |
| US-20110190349-A1 | TETRAHYDRO-PYRAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-04 | — | — | US | disclosed |
| US-20110190349-A1 | TETRAHYDRO-PYRAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-04 | — | — | US | disclosed |
| US-20110053904-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | US | disclosed |
| US-20110053904-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | US | disclosed |
| US-20110053904-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | US | disclosed |
| WO-2011023667-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011023667-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053904-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | GRIA1, GLRA1, GRIA3 | CNR1 25/4885CNR2 68/4885SLC6A9 212/4885 |
| US-20110190349-A1 | TETRAHYDRO-PYRAN DERIVATIVES | GLRA1, GRIA1, GLRA2 | CNR1 113/4885CNR2 193/4885SLC6A9 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.